NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) said Phase 3 KRYSTAL-12
study, evaluating KRAZATI or adagrasib as a monotherapy in patients with
pretreated locally advanced or metastatic non-small cell lung cancer harboring a
KRASG12C mutation, met the primary endpoint of progression-free survival and the
key secondary endpoint of overall response rate. Bristol Myers Squibb will
complete a full evaluation of the available data and will share the results.

Rafael Amado, President, Head of Global Oncology Research and Development, Zai
Lab, said: 'We are proud to have contributed to the KRYSTAL-12 study and are
looking forward to bringing adagrasib to patients in need in China.'

Zai Lab expects to submit the New Drug Application for adagrasib to the National
Medical Products Association for KRASG12C mutated NSCLC in second or later line
treatment in China in the current year.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX